Back to search results

ST-SBRT for Polymetastatic Solid Tumors

This study is looking at a special type of radiation therapy called spatiotemporal stereotactic body radiation therapy (ST-SBRT) for people with solid tumors that have spread to many parts of the body (polymetastatic). ST-SBRT uses very precise radiation to target tumors, aiming to kill cancer cells with fewer treatments and less harm to healthy tissue. Researchers want to see how safe and effective ST-SBRT is, especially for tumors as small as 2.0 cm. They will be checking for any side effects and how well the treatment shrinks tumors. To join, you must be at least 18 years old, have a good performance status (Karnofsky performance status > 60), and have more than 5 tumor spots, with at least one larger than 2 cm. The current recruitment status is unclear.

Study design
This is an interventional study with a planned enrollment of 20 participants. It is evaluating the safety and effectiveness of ST-SBRT.
What's involved
You would undergo blood sample collection, CT scans, and ST-SBRT treatments. The duration of these procedures is not specified.
Compensation
Not stated in the trial record.
Follow-up
Researchers will check for side effects within 3 months after your last ST-SBRT treatment and assess treatment effectiveness 4 weeks after any ST-SBRT fraction.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT05733949

Spatiotemporal Stereotactic Body Radiation Therapy for the Treatment of Patients With Polymetastatic Solid Tumors

Recruiting
EARLY_PHASE1Ages 18+InterventionalTreatment
City of Hope Medical Center
~20 participants
Updated 2026-08-19 on ClinicalTrials.gov
What's tested:Biospecimen CollectionComputed TomographyStereotactic Body Radiation Therapy

At a glance

Recruiting sites
1 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Incidence of adverse events
Measured over Within 3 months after the last spatiotemporal stereotactic body radiation therapy (ST-SBRT) fraction
+1 more outcome measured

Conditions

Metastatic Malignant Solid Neoplasm

Explore related trials

Solid Neoplasm

NCT05733949

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • City of Hope Medical Center

    Duarte, Californiastudy coordinator listed

    Recruiting

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Yi-Jen Chen · PRINCIPAL_INVESTIGATOR · City of Hope Medical Center

Who to contact

Yi-Jen Chen
[email protected]
626-218-4589
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Documented informed consent of the participant and/or legally authorized representative
Assent, when appropriate, will be obtained per institutional guidelines
Age: \>= 18 years
Karnofsky performance status \> 60
Poly-metastatic disease, \> 5 lesions, and with at least one lesion \> 2.0 cm, with limited treatment options, and ineligible for or in progression under the standard systemic therapy
Pre-screening assessment confirms that the intervention can be administered without exceeding dose constraint guidelines
Patients with brain metastases can be included but brain metastases must be treated prior to enrollment and follow up magnetic resonance imaging (MRI) 3 months after treatment shows stable findings
Spinal cord metastases are allowed as long as treatment with or without radiation is completed
Prior radiotherapy in general is allowed, as long as the composite plan meets dose constraints
Life expectancy \>= 3 months in the opinion of the treating investigators
Off systemic therapy for at least one month prior and one month after study intervention

Exclusion

Judgement by the investigator that the patient is unsuitable to participate in the study and the patient is unlikely to comply with study procedures, restrictions, and requirements
Those not eligible for SBRT after review by a radiation oncologist
Serous medical comorbidities precluding radiotherapy
Unable to undergo a CT scan
Pregnant and/or breastfeeding women are excluded from this study as these agents may have the potential for teratogenic or abortifacient effects. Female patients of childbearing potentially must have a negative urine or serum pregnancy test within 72 hours prior to receiving therapy
On active systemic therapy
Prospective participants who, in the opinion of the investigator, may not be able to comply with all study procedures (including compliance issues related to feasibility/logistics)

What this trial measures

  • Incidence of adverse eventsWithin 3 months after the last spatiotemporal stereotactic body radiation therapy (ST-SBRT) fraction

    Toxicity is defined as non-hematologic toxicity that is at least grade 3 (Common Terminology Criteria for Adverse Events version \[v\]5.0) and at least possibly related to the study treatment.

  • Effectiveness of ST-SBRT4 weeks after any ST-SBRT fraction

    Efficacy (corresponding to local treatment effect) is defined as a complete response (CR) or partial response (PR) per Response Evaluation Criteria in Solid Tumors (RECIST) v1.1 within an irradiated lesion, as detected by computed tomography (CT) scan 4 weeks after any ST-SBRT fraction and compared against the baseline CT scan performed prior to any study treatment.